


Targeted therapy drug helps women with aggressive breast cancer live longer

September 29 2019



Mammograms showing a normal breast (left) and a breast with cancer (right). Credit: Public Domain

A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common forms of the disease.



The results were presented during the press briefing and the Presidential Symposium at the 2019 European Society for Medical Oncology (ESMO) Congress 2019 by Dr. Dennis Slamon, chair of hematology/oncology and director of Clinical/Translational Research at UCLA's Jonsson Comprehensive Cancer Center. The findings also show the combination treatment is beneficial with the longest time of recurrence today in first-line therapy, and should become a first-line option in <u>postmenopausal women</u> with HR+/HER2- advanced <u>breast cancer</u>.

"Many people argue that the first type of treatment <u>women</u> with this type of metastatic cancer should receive is some other form of hormonal therapy and then wait to see if they respond to that treatment," Slamon said. "But we found there's a <u>significant difference</u> when you use the combination of ribociclib with hormone therapy as the first line of therapy. There is absolutely no reason to wait to give women this treatment. This should be the new standard."

Ribociclib is part of a class of CDK4/6 inhibitors that work by blocking the activity of proteins called cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.

The current results build upon prior data previously reported by Slamon and colleagues that ultimately helped lead to the Food and Drug Administration's approval of ribociclib. There are currently now three CDK4/6 inhibitors that have been approved by the FDA for combination treatment with standard hormone therapies.

The double-blind clinical trial involved 726 postmenopausal women who had advanced hormone-receptor positive/HER2- breast cancer. The trial included women who had not received prior endocrine therapy as well as patients who were in the first-line or second-line setting.



The results demonstrated a statistically significant improvement in survival with a 28% reduction in risk of death. At 42 months, the estimated rates of survival were 58% for the drug combination treatment and 46% for women who were treated with the hormone therapy alone.

The median progression-free survival with ribociclib plus fulevestrant in the first-line setting is the longest reported in a phase III trial in hormone-receptor positive/HER2- breast cancer at a median of 33.6 months, compared to 19.2 months for those in the <u>hormone therapy</u> only group.

This is the second Phase III clinical trial confirming that ribociclib increases overall survival—something very few trials are able to accomplish.

"Increasing <u>overall survival</u> is the hardest endpoint to move," Slamon said. "We're also seeing that the time of progression-free survival is the longest yet reported for any of the drugs in this class. And even when patients are off the drug, the effect seems to be long-lasting in terms of the benefit. It's important because this means we are helping women live longer and have a better quality of life."

Provided by University of California, Los Angeles

Citation: Targeted therapy drug helps women with aggressive breast cancer live longer (2019, September 29) retrieved 5 April 2023 from https://medicalxpress.com/news/2019-09-therapy-drug-women-aggressive-breast.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.